PRESS RELEASE published on 01/26/2024 at 14:00, 10 months 26 days ago Optimind Pharma - Debenture Conversion Optimind Pharma Corp. (CSE:OMND) announces agreement to convert $303,750 convertible debentures at $0.025/share, potentially issuing 23,333,500 shares. Optimind focuses on psychedelic therapies for mental health. Convertible Debentures Optimind Pharma Corp. CSE:OMND Psychedelic Therapies Mental Health
Published on 12/21/2024 at 01:30, 18 hours 6 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 18 hours 6 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 31 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 20 hours 6 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours 45 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 51 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 18:00, 1 day 1 hour ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 7 hours 18 minutes ago AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 7 hours 18 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024
